[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vivacelle Bio\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100521656","phase-3-a-phase-iii-open-label-randomized-controlled-study-of-vbi-s-in-the-treatment-of-hypovolemia-in-patients-with-septic-shock-vbi-s-02-100521656",false,"NCT06072430","A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)","A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock","VBI-S-02","Inclusion Criteria:\n\n1. Male or female at least 18 years of age.\n2. Evidence of bacterial infection demonstrated by positive blood culture and\u002For a known source of infection and\u002For an elevated procalcitonin of ≥ 2 ng\u002Fml.\n3. Patient has a mean blood pressure \\\u003C 65 mmHg that is unresponsive to fluids currently available on the market.\n4. Sequential Organ Failure Assessment (SOFA) score ≥ 5\n5. Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria:\n\n   * Lactate \\> 2 mmol\u002FL\n   * Fever \\> 38.3°C, or 101°F\n   * Hypothermia \\\u003C 36°C core temperature (\\\u003C96.8°F)\n   * Heart rate \\> 90\n   * Tachypnea (respiratory rate ≥ 20\u002Fmin)\n   * White blood cell count \\>12,000 or less than 4,000, or with \\>10% \"bands\" (immature forms)\n   * Elevated procalcitonin in serum (≥ 2ng\u002Fml)\n   * Arterial hypoxemia (PaO2\u002FFiO2 \\\u003C 300)\n   * Creatinine increase \\> 0.5 mg\u002FdL since hospital admission\n   * INR \\> 1.5 or aPTT \\> 60 seconds\n6. Documented dysregulated host response to an infection as indicated by an increase in SOFA score by ≥ 2 points after an infection per the SEPSIS 3 guideline.\n7. Receiving vasopressors to maintain the target MAP of 65 mmHg.\n\nExclusion Criteria:\n\n1. Patients with a ventricular assist device\n2. Acute coronary syndrome\n3. Pregnant\n4. Acute bronchospasm\n5. Acute Mesenteric ischemia\n6. Emergency major surgery\n7. Diagnosis of acute Hepatitis B or C.\n8. Hematologic or coagulation disorders including thrombocytopenia (platelet count \\\u003C50,000) and associated with hemodynamically significant active bleeding that causes a decrease in blood pressure.\n9. White blood cell count of \\\u003C 1000 mm3\n10. Current participation or participation in another experimental or device study within the last 30 days before the start of this study. Patient may be included if on other drugs are for COVID-19.\n11. Patients with a known allergy to soybeans or eggs\n12. Patient is hypervolemic with assessment by physician or physician extender ultrasound 12 hours before infusion of VBI-S if hypervolemia is suspected.\n13. Patient expected to expire within 12 hours.\n14. Patients with disturbances in normal fat metabolism such as pathologic hyperlipemia, lipid nephrosis, or acute pancreatitis with hyperlipidemia.","ALL","18 Years",{"count":20,"type":21},46,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.",[27,28,29],"Septic Shock","Sepsis","Hypovolemia","RECRUITING","2025-04-03",{"date":33,"type":34},"2025-04-04","ACTUAL",{"date":36,"type":34},"2024-08-06",{"date":38,"type":21},"2025-12",{"name":40,"class":41},"Vivacelle Bio","INDUSTRY",6,""]